• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

异基因造血细胞移植后类固醇依赖型急性移植物抗宿主病:危险因素和临床结局。

Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes.

机构信息

Blood and Marrow Transplant Program.

Department of Medicine.

出版信息

Blood Adv. 2021 Mar 9;5(5):1352-1359. doi: 10.1182/bloodadvances.2020003937.

DOI:10.1182/bloodadvances.2020003937
PMID:33656537
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7948274/
Abstract

Acute graft-versus-host disease (aGVHD) has various risk factors and outcomes. We defined distinct aGVHD treatment response groups based on response to first-line corticosteroids: steroid sensitive (SS), steroid resistant (SR), and the rarely studied steroid dependent (SD) aGVHD. In 1143 consecutive adult and pediatric allogeneic hematopoietic cell transplant recipients, 385 (34%) developed aGVHD, with 10% having SS aGVHD, 9% SD aGVHD, and 14% SR aGVHD. The only factor significantly associated with SD in comparison with SS was older age (odds ratio [OR], 3.9; 95% confidence interval [CI], 1.4-11.3, when comparing 18- to 60-year-olds with <18-year-olds). Factors significantly associated with SR in comparison with SS were unrelated donor (OR, 3.0; 95% CI, 1.2-7.4) and Minnesota high-risk aGVHD (OR, 2.4; 95% CI, 1.3-4.6). SR aGVHD was independently associated with higher risk for 2-year overall mortality (hazards ratio [HR], 1.8; 95% CI, 1.2-2.8) and nonrelapse mortality (NRM; HR, 2.1; 95% CI, 1.2-3.9). SS and SD GVHD groups had similar overall survival and NRM. The cumulative incidence of chronic GVHD was highest in the SD group, followed by the SR and SS groups (46%, 41%, and 29%, respectively). SD and SS GVHD had similar prognoses, both markedly better than those of the SR groups.

摘要

急性移植物抗宿主病(aGVHD)有多种危险因素和结局。我们根据对一线皮质类固醇的反应定义了不同的 aGVHD 治疗反应组:皮质类固醇敏感(SS)、皮质类固醇抵抗(SR)和研究较少的皮质类固醇依赖(SD)aGVHD。在 1143 例连续的成人和儿科异基因造血细胞移植受者中,有 385 例(34%)发生了 aGVHD,其中 10%为 SS aGVHD,9%为 SD aGVHD,14%为 SR aGVHD。与 SS 相比,唯一与 SD 显著相关的因素是年龄较大(优势比[OR],3.9;95%置信区间[CI],1.4-11.3,当比较 18-60 岁与<18 岁时)。与 SS 相比,与 SR 显著相关的因素是无关供体(OR,3.0;95%CI,1.2-7.4)和明尼苏达州高危 aGVHD(OR,2.4;95%CI,1.3-4.6)。SR aGVHD 与 2 年总死亡率(风险比[HR],1.8;95%CI,1.2-2.8)和非复发死亡率(NRM;HR,2.1;95%CI,1.2-3.9)升高独立相关。SS 和 SD GVHD 组的总生存率和 NRM 相似。SD 组慢性 GVHD 的累积发生率最高,其次是 SR 组和 SS 组(分别为 46%、41%和 29%)。SD 和 SS GVHD 的预后相似,均明显优于 SR 组。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a229/7948274/d37a2b3cc8c1/advancesADV2020003937absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a229/7948274/d37a2b3cc8c1/advancesADV2020003937absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a229/7948274/d37a2b3cc8c1/advancesADV2020003937absf1.jpg

相似文献

1
Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes.异基因造血细胞移植后类固醇依赖型急性移植物抗宿主病:危险因素和临床结局。
Blood Adv. 2021 Mar 9;5(5):1352-1359. doi: 10.1182/bloodadvances.2020003937.
2
Treatment-Responsive Acute Graft-versus-Host Disease after Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes.移植后环磷酰胺预防治疗后发生的治疗反应性急性移植物抗宿主病:发生率和临床结局。
Transplant Cell Ther. 2024 Jul;30(7):688.e1-688.e9. doi: 10.1016/j.jtct.2024.05.007. Epub 2024 May 9.
3
Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes.激素敏感型、依赖型和抵抗型急性移植物抗宿主病后的慢性移植物抗宿主病:发生率和临床结局。
Blood Adv. 2023 Jul 25;7(14):3644-3650. doi: 10.1182/bloodadvances.2022009505.
4
Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation.类固醇敏感,但非类固醇依赖或类固醇耐药的急性移植物抗宿主病,在异基因造血细胞移植后与无移植物抗宿主病相比,具有相似的感染风险。
Transplant Cell Ther. 2022 Aug;28(8):509.e1-509.e11. doi: 10.1016/j.jtct.2022.05.008. Epub 2022 May 14.
5
[Efficacy of basiliximab in the treatment of 87 cases of steroid-refractory or steroid-dependent acute graft-versus-host disease].巴利昔单抗治疗87例激素难治性或激素依赖性急性移植物抗宿主病的疗效
Zhonghua Xue Ye Xue Za Zhi. 2022 Feb 14;43(2):120-127. doi: 10.3760/cma.j.issn.0253-2727.2022.02.006.
6
Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.维得利珠单抗联合巴利昔单抗二线治疗激素难治性下胃肠道急性移植物抗宿主病。
Front Immunol. 2024 Jul 3;15:1408211. doi: 10.3389/fimmu.2024.1408211. eCollection 2024.
7
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial.间充质基质细胞联合巴利昔单抗、钙调磷酸酶抑制剂治疗激素耐药性急性移植物抗宿主病:一项多中心、随机、3 期、开放标签试验。
J Hematol Oncol. 2022 Mar 7;15(1):22. doi: 10.1186/s13045-022-01240-4.
8
[Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].[抗CD(25)单克隆抗体作为80例接受异基因造血干细胞移植的类固醇难治性急性移植物抗宿主病的挽救治疗]
Zhonghua Nei Ke Za Zhi. 2018 May 1;57(5):324-329. doi: 10.3760/cma.j.issn.0578-1426.2018.05.004.
9
Differential protein expression in endothelial cells exposed to serum from patients with acute graft-vs-host disease, depending on steroid response.急性移植物抗宿主病患者血清作用下,依激素反应的内皮细胞差异蛋白表达。
J Cell Mol Med. 2023 May;27(9):1227-1238. doi: 10.1111/jcmm.17712. Epub 2023 Apr 4.
10
Clinical Features, Treatment, and Outcome of Pediatric Steroid Refractory Acute Graft-Versus-Host Disease: A Multicenter Study.儿科类固醇难治性急性移植物抗宿主病的临床特征、治疗和转归:一项多中心研究。
Transplant Cell Ther. 2022 Sep;28(9):600.e1-600.e9. doi: 10.1016/j.jtct.2022.06.008. Epub 2022 Jun 16.

引用本文的文献

1
Successful treatment with mesenchymal stromal cells-Frankfurt am Main in a pediatric patient with steroid-refractory and ruxolitinib-refractory acute gastrointestinal graft-versus-host disease.间充质基质细胞 - 美因河畔法兰克福治疗一名患有类固醇难治性和芦可替尼难治性急性胃肠道移植物抗宿主病的儿科患者取得成功。
Ann Hematol. 2025 Jul 15. doi: 10.1007/s00277-025-06491-y.
2
Modern-Era Challenges in the Clinical Management of Graft-Versus-Host Disease.移植物抗宿主病临床管理中的现代挑战
Adv Exp Med Biol. 2025;1475:103-128. doi: 10.1007/978-3-031-84988-6_6.
3
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD.

本文引用的文献

1
Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness.难治性急性移植物抗宿主病:超越激素抵抗的新工作定义。
Blood. 2020 Oct 22;136(17):1903-1906. doi: 10.1182/blood.2020007336.
2
Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.随机多中心试验:西罗莫司对比泼尼松作为标准风险急性移植物抗宿主病的初始治疗:BMT CTN 1501 试验。
Blood. 2020 Jan 9;135(2):97-107. doi: 10.1182/blood.2019003125.
3
EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment.
新型 MAGIC 综合评分结合临床症状和生物标志物,可更好地预测急性移植物抗宿主病的治疗效果。
Blood. 2024 Aug 29;144(9):1010-1021. doi: 10.1182/blood.2024025106.
4
Treatment-Responsive Acute Graft-versus-Host Disease after Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes.移植后环磷酰胺预防治疗后发生的治疗反应性急性移植物抗宿主病:发生率和临床结局。
Transplant Cell Ther. 2024 Jul;30(7):688.e1-688.e9. doi: 10.1016/j.jtct.2024.05.007. Epub 2024 May 9.
5
Modeling Invasive Aspergillosis Risk for the Application of Prophylaxis Strategies.侵袭性曲霉病预防策略应用的风险建模
Open Forum Infect Dis. 2024 Feb 6;11(3):ofae082. doi: 10.1093/ofid/ofae082. eCollection 2024 Mar.
6
Generation of Human Regulatory Dendritic Cells from Cryopreserved Healthy Donor Cells and Hematopoietic Stem Cell Transplant Recipients.从冷冻保存的健康供者细胞和造血干细胞移植受者中生成人调节性树突状细胞。
Cells. 2023 Sep 28;12(19):2372. doi: 10.3390/cells12192372.
7
Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials.二线治疗类固醇难治性急性移植物抗宿主病患者:随机对照试验的系统评价和荟萃分析。
Front Immunol. 2023 Jun 20;14:1211171. doi: 10.3389/fimmu.2023.1211171. eCollection 2023.
8
Efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSC PLEB001) for the treatment of grade II-IV steroid-refractory acute graft-versus-host disease: a study protocol for a multicenter, randomized, double-blind, placebo-controlled, phase II trial.人脐带间充质干细胞(hUC-MSC PLEB001)治疗 II-IV 级激素耐药性急性移植物抗宿主病的疗效和安全性:一项多中心、随机、双盲、安慰剂对照、II 期临床试验研究方案。
Trials. 2023 May 3;24(1):306. doi: 10.1186/s13063-023-07305-0.
9
Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes.激素敏感型、依赖型和抵抗型急性移植物抗宿主病后的慢性移植物抗宿主病:发生率和临床结局。
Blood Adv. 2023 Jul 25;7(14):3644-3650. doi: 10.1182/bloodadvances.2022009505.
10
The efficiency of human umbilical cord mesenchymal stem cells as a salvage treatment for steroid-refractory acute graft-versus-host disease.人脐带间充质干细胞作为挽救治疗类固醇耐药性急性移植物抗宿主病的疗效。
Clin Exp Med. 2023 Oct;23(6):2561-2570. doi: 10.1007/s10238-022-00983-1. Epub 2023 Jan 4.
EBMT-NIH-CIBMTR 工作组关于移植物抗宿主病评估标准化术语和指导的立场声明。
Bone Marrow Transplant. 2018 Nov;53(11):1401-1415. doi: 10.1038/s41409-018-0204-7. Epub 2018 Jun 5.
4
A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.一种用于预测急性移植物抗宿主病对初始治疗的反应、生存率和移植相关死亡率的精细风险评分。
Biol Blood Marrow Transplant. 2015 Apr;21(4):761-7. doi: 10.1016/j.bbmt.2015.01.001. Epub 2015 Jan 10.
5
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.异体造血干细胞移植疾病风险指数的验证和优化。
Blood. 2014 Jun 5;123(23):3664-71. doi: 10.1182/blood-2014-01-552984. Epub 2014 Apr 17.
6
Risk factors for acute GVHD and survival after hematopoietic cell transplantation.造血细胞移植后急性移植物抗宿主病的危险因素和生存情况。
Blood. 2012 Jan 5;119(1):296-307. doi: 10.1182/blood-2011-06-364265. Epub 2011 Oct 18.
7
Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report.给予类固醇抵抗或依赖的急性移植物抗宿主病患者阿法西普后的快速反应:一项初步报告。
Bone Marrow Transplant. 2005 Dec;36(12):1097-101. doi: 10.1038/sj.bmt.1705185.
8
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.造血细胞移植(HCT)特异性合并症指数:一种用于异基因造血细胞移植前风险评估的新工具。
Blood. 2005 Oct 15;106(8):2912-9. doi: 10.1182/blood-2005-05-2004. Epub 2005 Jun 30.
9
Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.443例患者对作为急性移植物抗宿主病主要治疗方法的类固醇的反应:分级系统比较
Biol Blood Marrow Transplant. 2002;8(7):387-94. doi: 10.1053/bbmt.2002.v8.pm12171485.
10
Non-parametric inference for cumulative incidence functions in competing risks studies.竞争风险研究中累积发病率函数的非参数推断。
Stat Med. 1997 Apr 30;16(8):901-10. doi: 10.1002/(sici)1097-0258(19970430)16:8<901::aid-sim543>3.0.co;2-m.